← Leaderboards
Janet McGill
Washington University
$0
Attributed
$0
Total exposure
28
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 28
By mechanism
M01$0 · 28
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Colin G Nichols$27,441,621
- John Morris$91,785,862
- Quing Zhu$6,933,345
- Joseph P Culver$22,566,427
- Samuel Klein$33,055,933
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDiabetes Mellitus TherapyNoninsulin Dependent Diabetes MellitusDrug Screening /EvaluationHypoglycemic AgentsInsulinDrug Administration Rate /DurationCombination ChemotherapyLongitudinal Human StudyMetforminOral AdministrationMedical ComplicationDiabetic NephropathyCardiovascular Disorder ChemotherapyDiabetes MellitusHypertensionHemoglobin AsHypoglycemiaDiet TherapyBlood GlucoseDosageHormone Therapy
Grant awards (84)
GI262570 sodium tablets w/ metformin for 26 wks in NIDDM$0
M01 · FY2002 · RR
GI262570 sodium tablets monotherapy for 26wks in NIDDM$0
M01 · FY2002 · RR
Nabumetone, Celcoxib &ibuprofen on blood pressure control in hypertension$0
M01 · FY2002 · RR
Comparison of TCPI TD-glucose with finger stick methods$0
M01 · FY2002 · RR
EXTERNAL CONTINUOUS INFUSION OF INSULIN ASPART, LISPRO &BUFFERED REGULAR IN IDDM$0
M01 · FY2002 · RR
EXTERNAL CONTINUOUS SUBCUTANEOUS INSULIN ASPART INFUSION IN NIDDM$0
M01 · FY2002 · RR
INHALED HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2002 · RR
EFFECT OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM TREATED WITH METFORMIN$0
M01 · FY2002 · RR
INHALED VS. SUBCUTANEOUS HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2002 · RR
EVALUATION OF MULTI DOSE REGIMEN L-753,037 IN AFRICAN AMERICANS WITH HYPERTENSION$0
M01 · FY2002 · RR
PLANT STEROLS IN CHOLESTEROL ABSORPTION$0
M01 · FY2002 · RR
52 WEEK, ORLISTAT TREATMENT IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS$0
M01 · FY2002 · RR
ORAL GI262570X MONOTHERAPY 12WEEKS DURATION SUBJECTS WITH TYPE2 DIABETES$0
M01 · FY2002 · RR
REPAGLINIDE AND TROGLITAZONE IN TREATMENT OF TYPE II DIABETES MELLITUS$0
M01 · FY2002 · RR
BRL49653 COMBINATION WITH INSULIN TO PATIENTS WITH NONINSULIN DEPENDENT DIABETES$0
M01 · FY2002 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT AND AMLODIPINE IN TYPE II DIABETES$0
M01 · FY2002 · RR
SDZ DJN 608 MONOTHERAPY COMPARED TO GLIBENCLAMIDE MONOTHERAPY B304 E$0
M01 · FY2002 · RR
EARLY DIABETES INTERVENTION PROGRAM (EDIP)$0
M01 · FY2002 · RR
BRL49653C COMBINATION WITH GLYBURIDE TO PATIENTS WITH DIABETES$0
M01 · FY2002 · RR
METFORMIN AND GLYBURIDE COMBINATION PRODUCTS IN DIABETES PATIENTS$0
M01 · FY2002 · RR
26 WEEKS OF BRL 49653C GIVEN 2X DAY TO PATIENTS W/ NIDDM &INADEQUATE CONTROL$0
M01 · FY2002 · RR
EVALUATE 3 FIXED DOSES OF SDZ DJN 608 IN NIDDM$0
M01 · FY2002 · RR
RENAL PROTECTIVE EFFECTS OF LOSARTAN IN PATIENTS WITH NIDDM AND NEPHROPATHY$0
M01 · FY2002 · RR
OPEN LABEL LONG TERM TOLERABILITY OF PIOGLITAZONE AD 48333 IN NIDDM PATIENTS$0
M01 · FY2002 · RR
DIABETES REGISTRY--RESEARCH AND EDUCATION FACILITY$0
M01 · FY2002 · RR
ORAL ZOPOLRESTAT IN SUBJECTS WITH PERIPHERAL SYMMETRICAL DIABETIC POLYNEUROPATHY$0
M01 · FY2002 · RR
DIABETES CENTER--CLINICAL RESEARCH FACILITY, RESEARCH, AND TRAINING$0
M01 · FY2002 · RR
ORAL ZOLOLRESTAT IN NORMOTENSIVE, TYPE I DIABETICS WITH INCIPIENT NEPHROPATHY$0
M01 · FY2002 · RR
Comparison of TCPI TD-glucose with finger stick methods$0
M01 · FY2001 · RR
DIABETES REGISTRY--RESEARCH AND EDUCATION FACILITY$0
M01 · FY2001 · RR
ORAL ZOLOLRESTAT IN NORMOTENSIVE, TYPE I DIABETICS WITH INCIPIENT NEPHROPATHY$0
M01 · FY2001 · RR
DIABETES CENTER--CLINICAL RESEARCH FACILITY, RESEARCH, AND TRAINING$0
M01 · FY2001 · RR
ORAL ZOPOLRESTAT IN SUBJECTS WITH PERIPHERAL SYMMETRICAL DIABETIC POLYNEUROPATHY$0
M01 · FY2001 · RR
OPEN LABEL LONG TERM TOLERABILITY OF PIOGLITAZONE AD 48333 IN NIDDM PATIENTS$0
M01 · FY2001 · RR
RENAL PROTECTIVE EFFECTS OF LOSARTAN IN PATIENTS WITH NIDDM AND NEPHROPATHY$0
M01 · FY2001 · RR
EVALUATE 3 FIXED DOSES OF SDZ DJN 608 IN NIDDM$0
M01 · FY2001 · RR
26 WEEKS OF BRL 49653C GIVEN 2X DAY TO PATIENTS W/ NIDDM &INADEQUATE CONTROL$0
M01 · FY2001 · RR
METFORMIN AND GLYBURIDE COMBINATION PRODUCTS IN DIABETES PATIENTS$0
M01 · FY2001 · RR
BRL49653C COMBINATION WITH GLYBURIDE TO PATIENTS WITH DIABETES$0
M01 · FY2001 · RR
EARLY DIABETES INTERVENTION PROGRAM (EDIP)$0
M01 · FY2001 · RR
SDZ DJN 608 MONOTHERAPY COMPARED TO GLIBENCLAMIDE MONOTHERAPY B304 E$0
M01 · FY2001 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT AND AMLODIPINE IN TYPE II DIABETES$0
M01 · FY2001 · RR
BRL49653 COMBINATION WITH INSULIN TO PATIENTS WITH NONINSULIN DEPENDENT DIABETES$0
M01 · FY2001 · RR
REPAGLINIDE AND TROGLITAZONE IN TREATMENT OF TYPE II DIABETES MELLITUS$0
M01 · FY2001 · RR
ORAL GI262570X MONOTHERAPY 12WEEKS DURATION SUBJECTS WITH TYPE2 DIABETES$0
M01 · FY2001 · RR
52 WEEK, ORLISTAT TREATMENT IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS$0
M01 · FY2001 · RR
PLANT STEROLS IN CHOLESTEROL ABSORPTION$0
M01 · FY2001 · RR
EVALUATION OF MULTI DOSE REGIMEN L-753,037 IN AFRICAN AMERICANS WITH HYPERTENSION$0
M01 · FY2001 · RR
INHALED VS. SUBCUTANEOUS HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2001 · RR
EFFECT OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM TREATED WITH METFORMIN$0
M01 · FY2001 · RR
INHALED HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2001 · RR
EXTERNAL CONTINUOUS SUBCUTANEOUS INSULIN ASPART INFUSION IN NIDDM$0
M01 · FY2001 · RR
EXTERNAL CONTINUOUS INFUSION OF INSULIN ASPART, LISPRO &BUFFERED REGULAR IN IDDM$0
M01 · FY2001 · RR
Nabumetone, Celcoxib &ibuprofen on blood pressure control in hypertension$0
M01 · FY2001 · RR
GI262570 sodium tablets monotherapy for 26wks in NIDDM$0
M01 · FY2001 · RR
GI262570 sodium tablets w/ metformin for 26 wks in NIDDM$0
M01 · FY2001 · RR
DIABETES REGISTRY--RESEARCH AND EDUCATION FACILITY$0
M01 · FY2000 · RR
GI262570 sodium tablets w/ metformin for 26 wks in NIDDM$0
M01 · FY2000 · RR
GI262570 sodium tablets monotherapy for 26wks in NIDDM$0
M01 · FY2000 · RR
Nabumetone, Celcoxib &ibuprofen on blood pressure control in hypertension$0
M01 · FY2000 · RR
Comparison of TCPI TD-glucose with finger stick methods$0
M01 · FY2000 · RR
EXTERNAL CONTINUOUS INFUSION OF INSULIN ASPART, LISPRO &BUFFERED REGULAR IN IDDM$0
M01 · FY2000 · RR
EXTERNAL CONTINUOUS SUBCUTANEOUS INSULIN ASPART INFUSION IN NIDDM$0
M01 · FY2000 · RR
INHALED HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
EFFECT OF A-100 ON GLYCEMIC CONTROL IN OVERWEIGHT NIDDM TREATED WITH METFORMIN$0
M01 · FY2000 · RR
INHALED VS. SUBCUTANEOUS HUMAN INSULIN THERAPY IN TYPE 2 DIABETES$0
M01 · FY2000 · RR
EVALUATION OF MULTI DOSE REGIMEN L-753,037 IN AFRICAN AMERICANS WITH HYPERTENSION$0
M01 · FY2000 · RR
PLANT STEROLS IN CHOLESTEROL ABSORPTION$0
M01 · FY2000 · RR
52 WEEK, ORLISTAT TREATMENT IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS$0
M01 · FY2000 · RR
ORAL GI262570X MONOTHERAPY 12WEEKS DURATION SUBJECTS WITH TYPE2 DIABETES$0
M01 · FY2000 · RR
REPAGLINIDE AND TROGLITAZONE IN TREATMENT OF TYPE II DIABETES MELLITUS$0
M01 · FY2000 · RR
BRL49653 COMBINATION WITH INSULIN TO PATIENTS WITH NONINSULIN DEPENDENT DIABETES$0
M01 · FY2000 · RR
ANTIPROTEINURIC EFFECTS OF OMAPATRILAT AND AMLODIPINE IN TYPE II DIABETES$0
M01 · FY2000 · RR
SDZ DJN 608 MONOTHERAPY COMPARED TO GLIBENCLAMIDE MONOTHERAPY B304 E$0
M01 · FY2000 · RR
EARLY DIABETES INTERVENTION PROGRAM (EDIP)$0
M01 · FY2000 · RR
BRL49653C COMBINATION WITH GLYBURIDE TO PATIENTS WITH DIABETES$0
M01 · FY2000 · RR
METFORMIN AND GLYBURIDE COMBINATION PRODUCTS IN DIABETES PATIENTS$0
M01 · FY2000 · RR
26 WEEKS OF BRL 49653C GIVEN 2X DAY TO PATIENTS W/ NIDDM &INADEQUATE CONTROL$0
M01 · FY2000 · RR
EVALUATE 3 FIXED DOSES OF SDZ DJN 608 IN NIDDM$0
M01 · FY2000 · RR
RENAL PROTECTIVE EFFECTS OF LOSARTAN IN PATIENTS WITH NIDDM AND NEPHROPATHY$0
M01 · FY2000 · RR
OPEN LABEL LONG TERM TOLERABILITY OF PIOGLITAZONE AD 48333 IN NIDDM PATIENTS$0
M01 · FY2000 · RR
ORAL ZOPOLRESTAT IN SUBJECTS WITH PERIPHERAL SYMMETRICAL DIABETIC POLYNEUROPATHY$0
M01 · FY2000 · RR
DIABETES CENTER--CLINICAL RESEARCH FACILITY, RESEARCH, AND TRAINING$0
M01 · FY2000 · RR
ORAL ZOLOLRESTAT IN NORMOTENSIVE, TYPE I DIABETICS WITH INCIPIENT NEPHROPATHY$0
M01 · FY2000 · RR